Entity
  • Moovcare® by Sivan

    Created in 2014
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    17 2,085
  • Activities

  • Entity types

  • Location

    Paris, France

    Paris

    France

  • Employees

    Scale: 11-50

    Estimated: 15

  • Engaged corporates

    5
    0 4
  • Added in Motherbase

    9 months ago
Description
  • Value proposition

    early IS ON TIME!

    SIVAN is an e-health company committed to improve the lives of cancer patients worldwide.
    SIVAN developed Moovcare®, the first application that was clinically validated and proven to extend the life of lung cancer patients.
    Moovcare® helps physicians detect relapses and complications at early stage and provide the right treatment at the right time, therefore optimize the individual care management of lung cancer patients.

  • Original language

    early IS ON TIME!

    SIVAN INNOVATION : CONNECT HEALTH, IMPROVE LIFE

    At a time when connected items and eHealth set in the medical landscape, founded in 2014 in Jerusalem by Daniel ISRAEL, SIVAN Innovation is an Israeli E-health R&D company, serving healthcare
    professionals and patients essentially dedicated to design, evaluate/validate and develop web-application for disease management.

    SIVAN INNOVATION combines the precision of computer technologies, the experience in secured remote transmission, the scientific requirement and clinical expertise to provide medical devices to follow-up cancer patients in accordance to Quality Management System Requirement.

    SIVAN INNOVATION is the first company that evaluated the survival impact of such products in randomized phase II and III trials.

    SIVAN INNOVATION developped the first web-application for an early detection of symptomatic relapse or complications & allowing early supportive care in high-risk lung cancer patients between visits. Moovcare TM. This product is a Medical Device currently in a CE market procedure in Europe.

    The impact on survival was evaluated in a multi-institutional phase III randomized trial which compared web-application follow-up for which patient's self-scored symptoms that were weekly sent (between planned visits) to the oncologist and a clinical routine assessment with a CT-scan (every 3-6 months or at investigator's discretion).

    The phase III positive results was published in the JNCI https://academic.oup.com/jnci/article-abstract/109/9/djx029/3573360/Randomized-Trial-Comparing-a-Web-Mediated-Follow?redirectedFrom=fulltext

  • HOME - Moovcare® alerts you to the first signs of trouble so you can intervene sooner.

    HOME - Moovcare® alerts you to the first signs of trouble so you can intervene sooner.

  • https://www.moovcare.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Agence du numérique en santé Agence du numérique en santé
Other

2 Jul 2023


Ministère de la Santé Ministère de la Santé
Other

20 Nov 2023


Institut Curie
Institut Curie
Health, Hospitals and Health Care
Institut Curie
Health, Hospitals and Health Care
Other

13 Sep 2023


AstraZeneca
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
Other

25 Jul 2023


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Other

20 Apr 2019


Similar entities
Loading...
Loading...
Social network dynamics